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ABSTRACT: The synthesis of a series of cyclometalated gold(III)
complexes supported by pyrazine-based (C^N^C)-type pincer ligands
is reported, including the crystal structure of a cationic example. The
compounds provide a new platform for the study of antiproliferative
properties of gold(III) complexes. Seven complexes were tested: the
neutral series (C^Npz^C)AuX [X = Cl (1), 6-thioguanine (4), C
CPh (5), SPh (6)] and an ionic series that included the N-methyl
complex [(C^NpzMe^C)AuCl]BF4 (7) and the N-heterocyclic carbene
complexes [(C^Npz^C)AuL]+ with L = 1,3-dimethylbenzimidazol-2-
ylidene (2) or 1,3,7,9-tetramethylxanthin-8-ylidene (3). Tests against
human leukemia cells identiﬁed 1, 2, 3, and 4 as particularly promising,
whereas protecting the noncoordinated N atom on the pyrazine ring
by methylation (as in 7) reduced the cytotoxicity. Complex 2 proved to be the most eﬀective of the entire series against the
HL60 leukemia, MCF-7 breast cancer, and A549 lung cancer cell lines, with IC50 values down to submicromolar levels, associated
with a lower toxicity toward healthy human lung ﬁbroblast cells. The benzimidazolylidene complex 2 accumulated more
eﬀectively in human lung cancer cells than its caﬀeine-based analogue 3 and the gold(III) chloride 1. Compound 2 proved to be
unaﬀected by glutathione under physiological conditions for periods of up to 6 days and stabilizes the DNA G-quadruplex and i-
motif structures; the latter is the ﬁrst such report for gold compounds. We also show the ﬁrst evidence of inhibition of MDM2−
p53 protein−protein interactions by a gold-based compound and identiﬁed the binding mode of the compound with MDM2
using saturation transfer diﬀerence NMR spectroscopy combined with docking calculations.
■ INTRODUCTION
Metallodrugs are widely used for the treatment of several
disorders, such as diabetes,1 rheumatoid arthritis, and cancer.2
Since the late 1960s, cis-diamminedichloroplatinum(II) (cispla-
tin)3 has become one of the reference compounds in clinics for
the treatment of various types of cancer, including ovarian,
testicular, bladder, melanoma, nonsmall cell and small cell lung
cancers, lymphomas, and myelomas.4 However, despite its
success, cisplatin presents major drawbacks, such as a limited
spectrum of action, acquired resistance to treatment, and severe
side eﬀects, which limit the doses administrable to patients.5 In
the search for improvements, many diﬀerent platinum-based
complexes have been synthesized and tested as anticancer drugs
in the past decades; however, only two of them (carboplatin
and oxaliplatin) have reached worldwide approval.6 In the quest
for new metallodrugs with improved eﬃcacy, a larger spectrum
of action, the ability to overcome resistances, and decreased
side eﬀects, complexes based on other transition metals have
been explored, including Ti,7 Fe,8 Cu,9 Ru,10 and Au.11
Organometallic complexes of gold in the oxidation states +I
and +III have proved particularly promising for anticancer
purposes.12 Indeed, complexes bearing N-heterocyclic carbene
(NHC) ligands, alkynyl ligands, and cyclometalated arylpyr-
idine ligands are especially eﬃcient in stabilizing Au cations in
physiological environments. Special interest has focused in the
past few years on cyclometalated complexes in which the
Au(III) center is stabilized by (C^N), (C^N^N), or (C^N^C)
pincer ligands.12c,f,13 These complexes also present the
advantage of tolerating a large palette of ancillary ligands
such as phosphines,14,15 NHCs,16 and N-donor ligands,17,18
enabling optimization of their biological properties. Examples
of cyclometalated Au(III) complexes are depicted in Figure 1.
Gold complexes have been reported to often trigger their
antiproliferative eﬀects via direct interaction of the Au atom
with sulfur or selenium donor atoms of enzymes such as
thioredoxin reductase (TrxR),21 cathepsins,22 poly(adenosine
diphosphate (ADP)-ribose) polymerase 1 (PARP-1),23 and
aquaporins.24 Che and co-workers16 showed that although
compound B (Figure 1) could inhibit cancer cell proliferation
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at low-submicromolar concentrations, it reacted only poorly
with thioredoxin reductase. These authors also reported on the
high toxicity, good selectivity, and inhibition of topoisomerase I
by complexes of type A, a hydrolytically stable cyclometalated
Au(III)−NHC complex acting as a structural complex.
Although Au complexes have been shown not to interact
closely with plasmid DNA,17 recent reports have demonstrated
the ability of organometallic gold(I/III) complexes to stabilize
the G-quadruplex structure of DNA.25 G-quadruplexes are
secondary DNA structures formed in guanine-rich sequences by
stacking of several G-quartets (cyclic planar assemblies
constituted of four guanines maintained around a K+ cation
via a Hoogsteen hydrogen-bonding network).26 There is good
evidence for their occurrence within cell nuclei27 and for their
role in regulating key cellular events, including telomerase
activity and oncogene expression.28 i-Motifs are also DNA
secondary structures formed from sequences rich in cytosine
and are stabilized by intercalated, hemiprotonated cytosine−
cytosine base pairs.29 i-Motifs have been studied as potential
switches in nanotechnology.30 As i-motif-forming sequences
typically oppose regions that can also form G-quadruplexes and
stabilization of i-motifs has also been shown to have eﬀects on
both telomerase activity and oncogene expression,31 the
selective stabilization of G-quadruplexes or i-motifs is a
promising approach for the development of more selective
anticancer therapies.32
Metal complexes present a broad panel of geometries and
oxidation states, features that have been exploited for the design
of highly potent and selective metal-based enzyme inhib-
itors.33,34 The major strength of those systems is their ability to
ﬁt perfectly within the protein site due to the three-dimensional
(3D) arrangement of the ligands. The inhibition of protein−
protein interactions (PPIs) is emerging as a promising way to
treat cancer, and the best inhibitors have entered clinical
trials.35,36 Although most of the PPI inhibitors reported to date
are small lipophilic organic molecules, recent reports have
shown the potential of octahedral cyclometalated Ir(III)
complexes for PPI inhibition.37,38 Indeed, one of those was
shown to disrupt the interactions between tumor necrosis
factor α (TNF-α) and tumor necrosis factor receptor (TNFR)
more eﬃciently than the known organic inhibitor SPD304 by
ﬁtting more closely within the binding pocket.38 One of the
most studied PPIs is the E3 ubiquitin-protein ligase MDM2−
p53 interaction. Indeed, p53 acts as a tumor suppressor and is
found to have reduced activity in the majority of cancers. A
reason for reduced p53 activity is overexpression of MDM2,
which inhibits the p53 activity via PPI, making the disruption of
the interaction between MDM2 and p53 a very promising
target for the development of selective anticancer therapy.39
Although some cyclometalated (C^N)Au(III) complexes have
been reported to exhibit p53-dependent cytotoxic activity,14 to
the best of our knowledge, no gold-based complexes have yet
been reported to disrupt PPIs.
We recently reported the synthesis of a series of 2,6-bis(4′-
tert-butylphenyl)pyrazine (C^Npz^C)-type Au(III) complexes
(Figure 1, structure C; X = Cl, CCPh, SR).19,20 The
photoluminescence exhibited by these complexes may enable
the visualization of the uptake of the compounds and their
intracellular distribution by ﬂuorescence microscopy, which is
impossible to do with classical pyridine-based pincers.
Remarkably, (C^Npz^C)Au(III) complexes are not reduced
Figure 1. Examples of cyclometalated (C^N^C)Au(III) complexes
based on pyridine (A, B)15,16 and pyrazine (C) ligands19,20
Scheme 1. Synthesis of Pyrazine-Based (C^Npz^C)Au(III) Complexes 2−4 and Structures of the Previously Reported
Complexes 5−7; The Structure of 1 Shows the Numbering System Used for NMR Assignments
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by thiols, and the pyrazine rings in these planar ligands have a
tendency for hydrogen bonding as well as π stacking,20 all of
which may be relevant for understanding their biological
activity.
We report here the synthesis and characterization of three
new cyclometalated (C^Npz^C)Au(III) complexes: two cati-
onic complexes with NHC ligands, i.e., 1,3-dimethylbenzimi-
dazol-2-ylidene (2) and 1,3,7,9-tetramethylxanthin-8-ylidene
(3) (Scheme 1), and a neutral one with the known anticancer
agent 6-thioguanine (4). Although Au(I) complexes of 1,3,7,9-
tetramethylxanthin-8-ylidene and 6-thioguanine are
known,25b,40 this is the ﬁrst report of the use of these ligands
in Au(III) chemistry. These complexes together with
compounds 1 and 5−7 and the free pincer ligand HC^Npz^CH
(L) were screened for their antiproliferative properties at
concentrations of 10 and 1 μM on HL60 leukemia cells. The
IC50 values of the best candidates were then measured on the
HL60, MCF-7 (breast cancer), and A549 (human adenocarci-
noma lung cancer) cell lines as well as on MRC-5 cells (human
lung ﬁbroblasts) as a model of healthy cells. The responses
were compared with those of cisplatin. The uptake of the
compounds into the cells and the interactions with possible
intracellular targets were investigated.
■ RESULTS AND DISCUSSION
Synthesis and Characterization. The reaction of
(C^Npz^C)AuCl (1) with the N,N-dimethylbenzimidazolium
or xanthinium salts in the presence of potassium tert-butoxide
gave good yields of the ionic NHC complexes 2 and 3,
respectively (Scheme 1). The formation of the compounds was
conveniently monitored by 1H NMR spectroscopy. The
conversions of 1 to 2 and 3 were indicated by downﬁeld shifts
of the H8 proton by 0.9 and 0.7 ppm, respectively. The carbene
13C NMR signals for 2 and 3 were observed at δ13C{1H} = 162.5
and 159.1 ppm, respectively.
The reaction of 1 with 6-thioguanine (6-TG) in the presence
of potassium carbonate following reported procedures14,20 gave
the (C^Npz^C)Au(6-TG) (4) in good yield. The 1H NMR
signal of the H8 proton appeared at δ1H = 7.57 ppm and the
13C
NMR signal of the cyclometalated carbon C9 appeared at
δ13C{1H} = 170.2 ppm, in good agreement with what we obtained
for other (C^Npz^C)Au thiolates.20
Crystals of 2·toluene suitable for X-ray diﬀraction were
grown by slow evaporation of a saturated solution in
dichloromethane/toluene (9/1). The structure (Figure 2)
conﬁrms the distorted square-planar coordination sphere for
the Au(III) center. The bond distances lie within the range
expected for this type of complex. In particular, the Au1−
C25(carbene) distance of 1.995(10) Å in 2·toluene compares
well with those in other gold(III)−carbene complexes (1.967−
2.017 Å),41 In 2·toluene the carbene ligand is oriented roughly
perpendicular to the AuC2N plane (dihedral angle = 125.73°).
The crystal packing shows hydrogen-bonding interactions
between pyrazine rings of two neighboring molecules and
two PF6 anions conﬁning this dimerization (Figure 2). The
formation of this sort of {[(C^Npz^C)Au(NHC)](PF6)}2
dimer in the crystal lattice contrasts with the supramolecular
interactions found in pyridine-based (C^N^C)Au−carbene
complexes.41 As noted in the Introduction, the nature of this
sort of interaction is likely to be important to the understanding
of the biological activity of the complexes. As the X-ray crystal
structure suggests, the type and strength of the intermolecular
interactions are driven by the central ring of the cyclometalated
ligand.
Although insoluble in purely aqueous media, all of the
compounds appeared soluble enough in dimethyl sulfoxide
(DMSO) not to precipitate when diluted in aqueous media up
to 50 μM with 1% DMSO and up to 100 μM with 10% DMSO.
Photophysical Properties. Theranostics (compounds
associating an active drug with an imaging agent) enable
tracking of the drug after treatment and thus help elucidate the
drug’s mode of action.42 As we reported recently,19 the
photophysical properties of pyrazine-based complexes are
dominated by the (C^Npz^C) pincer ligand. On the basis of
those ﬁndings, we measured the photophysical properties of the
newly synthesized complexes (Table 1) to test whether they
were emissive enough to be tracked inside the cells. The most
relevant absorptions in the UV−vis spectrum are the
characteristic low-energy bands attributed to metal-perturbed
(C^Npz^C) singlet-state intraligand (1IL) transitions. The
intense green luminescence of all of the complexes is due to
(C^Npz^C) triplet-state intraligand (3IL) transitions, which
Figure 2. (left) Molecular structure of the cation in 2·toluene. The atomic numbering scheme is also shown. Selected bond distances [Å] and angles
[deg]: Au1−N1 1.991(9), Au1−C25 1.995(10), Au1−C6 2.099(10), Au1−C16 2.096(11), C6−Au1−C25 97.8(4), C16−Au1−C25 100.9(4),
torsion angle N1−Au1−C25−N3 125.73. (right) Crystal packing and hydrogen-bonding interactions involving the pyrazine moiety. Color coding: C
(gray), Au (yellow), N (blue), P (orange); F (light green); toluene (dark green).
Table 1. Photophysical Data for Complexes 2 and 3 in
CH2Cl2 Solution at 298 K
complex
λabs/nm
(10−3ε/M−1 cm−1) λem/nm (λex/nm) Φ/%a
2 278 (16.7), 321 (10.5),
345 (6.8), 409 (3.1),
430 (4.6), 456 (4.5)
536max, 571sh (300−420) 0.170
3 270 (23.7), 322 (7.34),
352 (5.3), 432 (2.4),
456 (2.3)
536max, 571sh (300−420) 0.170
aRelative to [Ru(bpy)3]
2+ in H2O as a standard (Φstn = 2.8%).
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show vibronic progression. The smaller energy gap of these
transitions in 2 and 3 compared with the pyridine analogues
under identical conditions enhances the ligand-to-ligand charge
transfer (LLCT) (NHC → C^Npz^C) character of the
transitions responsible for the low-energy absorption and the
emission. The quantum yields of both complexes are relatively
high for gold (C^N^C) pincer compounds in solution.
Although (C^Npz^C)Au(III) alkyl and aryl thiolates had
previously been found to be luminescent,20 the thiolate 4
proved not to be emissive in solution at room temperature.
This limits the use of luminescence for the visualization of the
intracellular uptake and localization of these compounds using
ﬂuorescence microscopy.
Antiproliferative Activity in Vitro. An initial screening of
compounds 1−7 was carried out on human promyelocytic
leukemia (HL60) cells. The inhibition of the proliferation of
HL60 cells was determined using the established MTS assay
(see the Experimental Section) after 72 h of incubation with 1−
7, the free pincer ligand (L), or cisplatin at a concentration of
10 or 1 μM (Figure 3). All of the gold compounds as well as the
free ligand L were predissolved in DMSO and then diluted 100-
fold in the culture medium containing the cells to reach the
ﬁnal concentration of compound and the nontoxic ﬁnal DMSO
concentration of 1%. Cisplatin was dissolved in water and
further diluted 100-fold with the culture medium with cells
following the method used for the other compounds.
At a concentration of 10 μM, the various types of ancillary
ligands gave very diﬀerent cell viability responses. While the
compounds containing NHC ligands (2 and 3) and the
compound bearing the anticancer moiety 6-TG (4) completely
inhibited cell proliferation, the neutral alkynyl and thiopheno-
late complexes (5 and 6, respectively) were nontoxic.
Methylation of the pyrazine N atom, as in compound 7,
strongly reduced the cytotoxicity compared with the non-
methylated analogue 1, which fully inhibited cell growth at the
same concentration; the presence or absence of a positive
charge on the (C^Npz^C)Au framework is therefore not in
itself a decisive factor. As a control, at 10 μM the free 2,6-
diarylpyrazine ligand L itself did not show any toxic eﬀect.
Reducing the concentration to 1 μM allowed further
discrimination. The caﬀeine-derived NHC complex 3 was
nontoxic at that concentration, and compounds 1 and 4 were
only moderately active (cell viability of 72% and 60%,
respectively), whereas the benzimidazolylidene complex 2
showed strong antiproliferative activity, with the cell viability
reduced to 22%.
The four compounds that showed strong cytotoxic eﬀects at
a concentration of 10 μM (i.e., 1−4) were selected for the
determination of values of IC50 (i.e., the concentration required
to inhibit 50% of cells from growing) on a panel of human
cancer cell lines, including leukemia (HL60), breast adeno-
carcinoma (MCF-7), and human lung adenocarcinoma (A549)
cells and, for comparison with healthy cells, human fetal lung
ﬁbroblast (MRC-5) cells. The results are reported in Table 2.
Compound 2 bearing the benzimidazole-based NHC ligand
proved to be the most toxic of the series; its IC50 values in the
micromolar to submicromolar range were 1 order of magnitude
lower against all cancer cell lines than those of complexes 1 and
3 and cisplatin. The exception was the highly resistant A549 cell
line, against which 2 was only 4 times more toxic than cisplatin.
Despite the close structural similarity between NHC com-
pounds 2 and 3, there was a dramatic diﬀerence in cytotoxic
eﬀects, with 2 being up to 14 times more potent than 3 against
MCF-7 cells.
The A549 cell line is known to exhibit cisplatin resistance
(due to overexpression of DNA repair enzymes such as
apurinic/apyrimidinic endonuclease 1 (APE1) or PARP),43 and
we found a decrease in activity for all of the tested compounds
against A549 compared with the HL60 and MCF-7 cell lines.
However, while compounds 1 and 3 appeared completely
nontoxic up to a concentration of 50 μM and compound 4
appeared weakly toxic (IC50 = 29.0 ± 1.8 μM) against A549
cells, the activity of 2 was encouragingly high, with an IC50 of
7.8 ± 1.3 μM. It appears that the highly polar caﬀeine-based
NHC ligand is very much less eﬀective than the hydrophobic
benzimidazolylidene ligand.
It is worth mentioning that although no strict direct
comparison with other reported (C^N^C)Au NHC complexes
is possible because they were tested against diﬀerent cell lines,
complex 2 presents IC50 values in the same low- to
submicromolar range as previously reported complexes.15,16
Figure 3. Inhibition of HL60 cell proliferation by (C^Npz^C)Au(III)
complexes 1−7; data represent the average ± standard error of three
experiments.
Table 2. Eﬀects of Compounds 1−4, 6-TG, and Cisplatin on
Cell Viability in Human Leukemia (HL60), Human Breast
Adenocarcinoma (MCF-7), Human Lung Adenocarcinoma
Epithelial (A549), and Human Fetal Lung Fibroblast (MRC-
5) Cells after 72 h of Incubation
IC50 ± SE (μM)
a
compound HL60 MCF-7 A549 MRC-5
1 3.71 ± 0.29 8.6 ± 1.1 >50 4.9 ± 0.6
2 0.31 ± 0.15 0.56 ± 0.02 7.8 ± 1.3 1.4 ± 0.4
3 4.05 ± 0.43 7.90 ± 0.13 >50 17.6 ± 1.9
4 0.90 ± 0.22 0.78 ± 0.11 29.0 ± 1.8 4.3 ± 0.7
cisplatin 3.70 ± 0.25 21.2 ± 3.9 33.7 ± 3.7 10.7 ± 3.0
6-TG 0.98 ± 0.07 0.42 ± 0.13 >50 >50
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Compared with related Au(I) NHC complexes, the Au(III)
complex 2 turned out to be more than twice as toxic as
(benzimidazolylidene)AuCl against A549 cells25b and more
than 10 times more toxic against MCF-7 cells.44 Moreover, the
toxicities of complex 2 against A549 and MCF-7 cells compare
well with those of [(benzimidazolylidene)2Au]
+.25b,45 Encour-
agingly, both 2 and 3 were 2−4 times less toxic toward healthy
ﬁbroblasts (MRC-5) than toward the HL60 and MCF-7 cancer
cell lines, although of course further improvements in selectivity
will be required for the future development of these potential
drugs.
Compound 4 was toxic at submicromolar levels against
HL60 and MCF-7 cells (IC50 = 0.90 ± 0.22 and 0.78 ± 0.11
μM, respectively) and weakly toxic against A549 cells (IC50 =
29.0 ± 1.8 μM), following exactly the toxicity pattern of its
ligand, 6-TG. While free 6-TG appeared nontoxic against
healthy ﬁbroblasts, compound 4 showed toxicity in the low-
micromolar range (IC50 = 4.3 ± 0.7 μM) and a similar
selectivity ratio as compounds 2 and 3. Compound 6, the
thiophenolate analogue of 4, was shown to be completely
inactive and demonstrates the poor cytotoxicity of the
(C^Npz^C)AuS moiety. These data suggest that the cytotoxic
properties of 4 might arise predominantly from the 6-TG ligand
rather than from the (C^Npz^C)Au scaﬀold.
Cellular Uptake. Cellular uptake and accumulation are
major factors involved in the cytotoxicity of drugs.46 In order to
measure the amount of compound taken up by the cells, we
quantiﬁed the cellular gold content using inductively coupled
plasma mass spectrometry (ICP-MS). We selected for that
study the most cytotoxic compound 2, its caﬀeine analogue 3,
and the starting chloride 1 to investigate the impact of the
NHC ligand and its nature on the cellular uptake. We used the
A549 cells, which gave the most important discrimination
between nontoxic compounds 1 and 3 and highly cytotoxic 2,
and the MCF-7 cells, which were sensitive to compounds 1−3.
Considering the respective IC50 values for 2 against A549 and
MCF-7 cells, these cell lines were incubated for 6 h with 10 μM
and 1 μM solutions of the gold compounds, respectively, as
described in the Experimental Section. The results of three
independent experiments are depicted in Figure 4 for A549
cells and in Figure S1 for MCF-7 cells.
Remarkably, compound 2 shows a much higher uptake into
A549 cells than either 1 or 3. Indeed, the intracellular gold
concentration of 2 was almost 4 and 11 times higher than those
of 1 and 3, respectively, in good agreement with the results of
the in vitro screening. The diﬀerence between the structurally
analogous cationic NHC complexes 2 and 3 is particularly
striking. Evidently, the presence of polar functional groups on
the caﬀeine-based NHC ligand of 3 impedes rather than assists
the uptake process into cancer cells. Similar behavior was
noticed with MCF-7 cells (Figure S1), conﬁrming the
deleterious impact of the methylcaﬀeinylidene ligand on the
cell uptake of the (C^Npz^C)Au−NHC scaﬀold.
Reaction of 2 with Glutathione. Glutathione (GSH) is a
tripeptide that is present at millimolar levels inside cells and is
overexpressed in most cancer cells. GSH is involved in many
diﬀerent cellular functions, such as xenobiotic detoxiﬁcation,
reactive oxygen species (ROS) scavenging, and cellular redox
balance maintenance.47 GSH has been shown to be involved in
the mechanism of cisplatin resistance (a) by reducing the
intracellular amount of cisplatin via multidrug resistance
protein-2 (MRP-2)-mediated eﬄux and (b) by acting as a
redox-regulating agent.48 GSH is known to deactivate Au(III)
complexes by reduction to Au(I) or Au(0). Reduction by GSH
has even been observed in Au(III) complexes bearing (N^N)
or (N^N^N) chelating ligands, leading to deactivation of the
compounds.49
We investigated the reactivity of the most promising
compound, 2, with GSH by 1H NMR spectroscopy by
monitoring mixtures of equimolar amounts of 2 and GSH
(10 mM) in DMSO-d6 over a period of 6 days at room
temperature, following the procedure described for Pt(IV)
complexes.50 The aromatic regions of the diﬀerent spectra are
presented in Figure S2. Over that period of time there was
neither reduction to Au(0) or Au(I) nor the appearance of the
signals corresponding to the free ligand, HC^Npz^CH.
Evidently, pyrazine-based Au(III) pincer complexes are
resistant to reduction by GSH, at least over the duration of
the experiment, i.e., the NHC ligand is not substituted during
these reactions. As we showed recently, stable (C^Npz^C)AuSR
complexes can indeed be isolated under diﬀerent conditions,
but these too are resistant to reduction.20 Additionally, in
contrast to what has been observed by Che et al. on (C^N)-
and (N^N^N)Au(III) complexes,18,49b no substitution reaction
by GSH of either the NHC ligand or one arm of the
(C^Npz^C) pincer ligand was observed. Taken together, these
data conﬁrm the high stability of 2 toward GSH. The data
therefore suggest that 2 is unlikely to trigger its antiproliferative
eﬀects via direct coordination of sulfur-donor-containing
enzymes like TrxR or PARP-1 as reported for other Au(III)
complexes.14,15,21 Thus, compound 2 might be considered as a
structural type that interacts with its targets via supramolecular
interactions.
DNA-Binding Properties. G-quadruplexes are secondary
structures of DNA formed by stacking of tetrads of guanine
residues linked via Hoogsteen hydrogen bonding and stabilized
by the presence of typically monovalent cations in the center of
the tetrad.28 The selective stabilization of those structures has
been investigated as a means of controlling key cellular events
such as telomerase activity and oncogene expression,29 making
the development of G-quadruplex ligands promising anticancer
candidates.33 Recent reports on organometallic Au(I/III)
complexes have highlighted the G-quadruplex structure of
DNA as a possible intracellular target for these classes of
Figure 4. Cell uptake of compounds 1−3 by A549 cells after 6 h of
treatment with compounds at 10 μM in DMSO. The signiﬁcance of
the results was analyzed by the t test: *, p < 0.05.
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compounds.25 Recently, a caﬀeine-based bis(NHC)gold(I)
cation has been cocrystallized with a G-quadruplex, showing
that the DNA−ligand interaction occurred via π stacking on the
accessible tetrads.25d
Another possible target for complex−DNA interactions are i-
motifs. These are cytosine-rich sequences that can form higher-
order structures via hydrogen bonding between hemiproto-
nated pairs of cytosines.31 i-Motifs require sequences that have
stretches of multiple cytosines and thus are likely to form in the
complementary strands opposing G-quadruplexes in the
genome. Although they are inherently less stable than G-
quadruplexes, the stabilization of i-motifs has been shown to
alter gene expression of the oncogene bcl-2 and disrupt
telomerase function, therefore also indicating potential as a
target for anticancer drugs.51 Considering that (C^N^C)Au−
NHC complexes have been demonstrated to be able to enter
the cell nucleus52 and in view of the structure of our best
candidate in the antiproliferative assay (planar with a large π
surface and monocationic charge) and the general high stability
of our (C^Npz^C)Au(III) complexes toward GSH, we screened
the compounds for their potential to bind to DNA G-
quadruplex and i-motif structures.
To give a broad indication of the DNA binding capabilities,
compounds 1−7 were assessed with the established Förster
resonance energy transfer (FRET) DNA-melting assay53
against diﬀerent DNA targets: the G-quadruplex-forming
sequence from the human telomere (hTeloG), the human
telomeric i-motif sequence (hTeloC), an i-motif-forming
sequence from the promoter region of the oncogene hif-1α,
and double-stranded DNA. The i-motif-forming sequence from
the human telomere is not stable at neutral pH, so this was
assessed at pH 5.5, where the structure is folded, and at the
transitional pH 6.0, where it is 50% folded.54 The remaining
sequences were all tested at the transitional pH of hif-1α, pH
7.2.55
From that preliminary screening using 50 equiv of
compounds (Figure 5), it was evident that both NHC
complexes 2 and 3 presented good interactions with both the
G-quadruplex and i-motif structures, whereas none of other
complexes interacted with any of the tested structures,
including double-stranded DNA. Somewhat surprisingly, this
was also the case for the cationic N-methyl complex 7, so the
presence of charge alone is not responsible for DNA
interactions. Moreover, the neutral complex 5 bearing a
phenylacetylenyl ligand with an extended π surface did not
show any interaction with the studied DNA structures. This
suggests that the good interactions of the cationic NHC
complexes 2 and 3 may be due to the combination of the
cationic charge, the increase in the π surface, and hydrogen
bonding to the noncoordinated pyrazine N atom. The neutral
compound 4 bearing a thioguanine ligand (of the same nature
as the components of G4 tetrads) did not show any interaction
with the studied DNA structures, as noticed for its thiophenol
analogue 6.
Both NHC-based compounds 2 and 3 interact in a dose-
dependent manner with all of the DNA structures (see Figures
S3 and S4). Compounds 2 and 3 were found to interact more
strongly with the human telomeric G-quadruplex sequence
(ΔTm up to 40 and 31 °C at [Au] = 20 μM for 2 and 3,
respectively) than with either the hif-1α i-motif sequence (ΔTm
up to 31 and 24 °C at [Au] = 20 μM for 2 and 3, respectively)
or the human telomeric i-motif sequence.
While 3 does not show any particular diﬀerence in its
interaction with either the human telomeric i-motif sequence at
both pH 5.5 and pH 6.0 or with hif-1α at pH 7.2, 2 seemed to
stabilize the telomeric i-motif structure at pH 6.0 more
eﬃciently than at pH 5.5; it also stabilized hif-1α at
physiological pH (pH 7.2). To the best of our knowledge,
this is the ﬁrst report of gold complexes stabilizing an i-motif
structure of DNA.
Replacing the benzimidazole-based carbene by a caﬀeine-
based one reduced the ability of the compound to interact with
classical double-stranded DNA (ΔTm up to 14 and 7 °C at 20
μM 2 and 3, respectively), as previously observed in the case of
bis(NHC)Au(I) complexes.25b
Inhibition of MDM2−p53 Interaction. Considering that
both MCF-7 and A549 cells present wild-type p53,56 the
interactions of our compounds with MDM2 and their ability to
disrupt the MDM2−p53 interaction were also explored.
Compounds 1−3 and 5 and the free ligand L were screened
as potential inhibitors using a ﬂuorescence polarization assay as
previously described.57 Human MDM2 protein (residues 17−
125) was used in the polarization assay, and the wild-type p53
peptide (residues 15−27) was used as a positive control.
Among the three gold-based complexes and the free ligand
screened at a concentration of 100 μM, only compounds 1 and
2 appeared to disrupt the MDM2−p53 interaction, highlighting
ﬁrst the relevance of the gold cation and second the impact of
the ancillary ligand. Compounds 1 and 2 were further evaluated
to determine their IC50 values. The most eﬃcient inhibitor was
2, with an IC50 of 31.1 ± 1.1 μM, while 1 has an IC50 of 48.8 ±
3.1 μM.
After the positive ﬂuorescence polarization results, the
interaction of compound 2 with MDM2 was conﬁrmed using
high-resolution saturation transfer diﬀerence NMR spectrosco-
py (STD NMR).58 STD NMR has already been demonstrated
to be a powerful tool to characterize pharmacophoric
information on the binding of ligands to MDM2.59 In our
case, STD NMR experiments clearly conﬁrmed the binding of 2
to MDM2 in solution (Figure 6), in agreement with the
ﬂuorescence polarization results. Clear signals were observed in
Figure 5. Stabilization of diﬀerent DNA structures (0.2 μM) by
pyrazine-based (C^Npz^C)Au complexes 1−7 at 10 μM measured by
FRET DNA-melting assay. Data represent the average and standard
deviation of three experiments.
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the diﬀerence spectrum, arising from the transfer of saturation
from the protein, which can only occur in the bound state
(Figure 6, bottom). In contrast, glycerol and residual DMSO
signals did not appear in the diﬀerence spectrum.
From the intensities of the STD NMR experiments we were
able to depict the binding epitope of 2 for the interaction with
MDM2, mapping in this way the main ligand contacts in the
binding pocket of MDM2 (Figure 6 inset). This was done by
normalization of all of the STD intensities against the strongest
one (Figure 6 inset). As the average deviation of epitope
mapping by STD NMR has been previously determined to be
around 7%,60 the values in Figure 6 show a highly
homogeneous distribution of normalized STD values (Figure
6 inset), indicating that 2 contacts MDM2 all along its structure
in the bound state. In this way, the experimental NMR data
support a binding mode in which 2 is almost fully buried in the
p53-speciﬁc hydrophobic binding pocket of MDM2, which is in
agreement with the hydrophobic character of the compound
and the typical binding of small ligands to MDM2.
To further investigate the structural details of the binding of
2 to MDM2 and to provide a 3D model of the complex, we
carried out docking calculations in a model of MDM2. The
interaction between MDM2 and p53 is well-characterized;
crystallization of the domains involved and mutagenesis studies
have clariﬁed the structures involved and the main features of
the interaction.61 An amphiphilic α-helix near the N-terminus
of p53 (amino acids 18−26) interacts with a hydrophobic cleft
at the N-terminal domain of MDM2. The most relevant
residues of p53 involved in the interaction are Phe19, Trp23,
and Leu26, occupying the deep pockets available on the
interaction surface of MDM2. A number of synthetic molecules
have been shown to take advantage of this binding epitope to
inhibit the interaction between MDM2 and p53.57,62
According to the results previously described in this paper,
direct interaction with methionine residues as main mode of
binding was excluded, and focus was given to the docking of the
molecule directly into the pockets occupied by p53. The result
of the docking calculations of 2 and MDM2 is shown in Figure
7 (for details on the calculations and analysis, see the
Experimental Section). Compound 2 sits with the ancillary
ligand partially in the pocket occupied by Leu 26 of p53. One of
the tert-butyl groups lies on the Phe 19 pocket while the
opposite one lies near the N-terminus of MDM2. The
(C^Npz^C) ligand lies against the α-helix between residues
50 and 63. Such an interaction also obstructs access to the Trp
23 pocket, which is enclosed by the ligand. The interactions are
mainly due to contacts with hydrophobic residues, whereas
speciﬁc hydrogen bonds and π interactions were not identiﬁed.
The ligand is completely buried in the p53-speciﬁc binding
pocket of MDM2, in very good agreement with the
homogeneous distribution of STD values observed in the
binding epitope determined by NMR experiments (Figure 6).
When assembled all together, these data enable us to draw a
preliminary picture of the impact of the ancillary ligands on the
biological properties of the (C^Npz^N)Au(III) complexes. First
of all, complex 4 bearing the known anticancer agent 6-TG as
the ancillary ligand seemed to possess cytotoxic properties very
similar to those of its ligand. In that particular case, the
biological properties may be due only to the ancillary ligand
rather than to the Au(III) part. Complexes 1 and 3 were shown
to have moderate activities. Indeed, both compounds appeared
to be poorly taken up into A549 and MCF-7 cancer cells but
were active against a potential intracellular target (i.e., MDM2−
p53 or G4 and i-motif DNA structures for 1 or 3, respectively).
Figure 6. Interaction of 2 with MDM2 in solution studied by STD
NMR (13.5 μM MDM2, 500 μM 2, 1% DMSO-d6, 800 MHz, 25 °C).
(top) 1H NMR reference spectrum. The inset shows the group
epitope mapping of 2 from STD NMR experiments derived from STD
NMR intensities at very low saturation time (0.5 s). Ligand hydrogens
showing high % values have close contacts with the surface of the
binding pocket of MDM2. (bottom) STD NMR spectrum (4 s
saturation time) showing signals of 2 resulting from the binding in
solution (intense signals around 3.5−3.7 ppm in the reference
spectrum belong to glycerol, which does not bind to MDM2.
Figure 7. Representation of 2 (gray) docked in MDM2 (PDB entry 1T4E, green). On the left, the side chains of residues surrounding 2 (closer than
4 Å) are displayed. On the right, the surface of MDM2 and relevant pockets occupied by p53 residues are indicated.
Inorganic Chemistry Article
DOI: 10.1021/acs.inorgchem.7b00339
Inorg. Chem. XXXX, XXX, XXX−XXX
G
This demonstrates the balance between uptake and reactivity
that a drug candidate must fulﬁll in order to be active. Finally,
complex 2, which presented high cytotoxicity, fulﬁlled all of the
requirements by being the most readily taken up into the cell
and being active against all of the tested intracellular targets.
■ CONCLUSION
We have reported the synthesis and characterization of three
new pyrazine-based cyclometalated (C^Npz^C)Au(III) com-
plexes. The crystal structure of one of these has been
determined and revealed the typical slightly distorted square-
planar geometry of cyclometalated (C^Npz^C)Au(III) com-
plexes. The antiproliferative screening of a series of seven
cyclometalated (C^Npz^C)Au(III) complexes, including the
newly synthesized ones, on HL60 cells revealed compounds 1−
4 as the most promising candidates. Compound 2 bearing a
1,3-dimethylbenzimidazol-2-ylidene ligand was shown to be the
most active complex, with IC50 values down to nanomolar
levels against cancer cells, although this was associated with
comparatively high cytotoxicity against healthy ﬁbroblasts. The
uptake study using ICP-MS and ﬂuorescence microscopy
revealed that compound 2, the most toxic complex, was present
in A549 and MCF-7 cells at the highest concentrations.
Compound 2 was shown by NMR spectroscopy to be highly
stable toward GSH at room temperature over a time period of 6
days. Compound 2 also interacted more tightly with G-
quadruplex DNA structures than its caﬀeine-based analogue 3.
Moreover, we have found the ﬁrst evidence that gold complexes
can stabilize i-motif DNA structures at both acidic and
transitional pH values. We have also reported for the ﬁrst
time the inhibition of the MDM2−p53 interaction by gold-
based complexes, which sheds new light on the possible
intracellular targets of such cyclometalated complexes and
might open the way for the optimization of new PPI inhibitors.
Overall, our study documents the importance of ancillary
donorhere the NHC ligandfor the biological properties of
cyclometalated Au(III) complexes. Benzimidazole-based NHC
ligands appear to be particularly promising for the development
of gold-based anticancer treatments. Further studies are
ongoing to increase the selectivity of the complexes by
targeting them to speciﬁc cancer cells.
■ EXPERIMENTAL SECTION
General Remarks. When required, manipulations were performed
using standard Schlenk techniques under dry nitrogen or in an
MBraun glovebox. Nitrogen was puriﬁed by passing it through
columns of supported P2O5 with moisture indicator and activated 4 Å
molecular sieves. Anhydrous solvents were freshly distilled from
appropriate drying agents. 1H and 13C{1H} spectra were recorded
using a Bruker Avance DPX-300 spectrometer. 1H NMR spectra
(300.13 MHz) were referenced to the residual protons of the
deuterated solvent used. 13C{1H} NMR spectra (75.47 MHz) were
referenced internally to the D-coupled 13C resonances of the NMR
solvent. Elemental analyses were carried out at London Metropolitan
University. UV−vis absorption spectra were recorded using a
PerkinElmer Lambda 35 UV−vis spectrometer. Excitation and
emission spectra were measured in a (TCSPC) Horiba Jobin Yvon
FluoroLog spectroﬂuorometer. Compounds 1, 5, 6, and 7 were
synthesized following reported procedures.19,20
Synthesis and Characterization. [(C^Npz^N)Au(1,3-dimethyl-
benzimidazol-2-ylidene)]PF6 (2). A mixture of [(C^N
pz^N)AuCl (1)
(50 mg, 0.087 mmol), 1,3-dimethylbenzimidazolium iodide (24 mg,
0.087 mmol), KOtBu (12 mg, 0.104 mmol), and KPF6 (48 mg, 0.261
mmol) was stirred in distilled toluene (6 mL) at 80 °C overnight,
leading to the formation of an orange precipitate. After the solution
was cooled to room temperature, the solvent was evaporated, and the
orange solid was dissolved in dichloromethane. The orange solution
was ﬁltered through Celite and concentrated under reduced pressure.
Upon addition of light petroleum (bp 40−60 °C), an orange
precipitate formed and was collected and dried to aﬀord the pure
product as an orange powder (54 mg, 0.065 mmol, 75% yield). Anal.
Calcd for C33H36N4AuPF6 (830.2): C, 47.72; H, 4.37; N, 6.75. Found:
C, 47.66; H, 4.48; N, 6.76. 1H NMR (CD2Cl2, 300.13 MHz): δ 8.99
(s, 2H, H2), 7.84 (m, 2H, H12), 7.80 (d, 3JH−H = 8.2 Hz, 2H, H
5), 7.72
(m, 2H, H13), 7.44 (dd, 3JH−H = 8.4 Hz,
4JH−H = 2.0 Hz, 2H, H
6), 6.98
(d, 4JH−H = 2.0 Hz, 2H, H
8), 4.16 (s, 6H, N−CH3), 1.18 (s, 18H, tBu).
13C{1H} NMR (CD2Cl2, 75.48 MHz): δ 165.3 (s, C
9), 162.5 (s, C10),
158.0 (s, C3/4), 157.3 (s, C3/4), 145.0 (s, C7), 139.8 (s, C2), 134.6 (s,
C11), 133.3 (s, C8), 127.3 (s, C5), 126.6 (s, C13), 125.9 (s, C6), 112.5
(s, C12), 36.5 (s, N−Me), 35.6 (s, C(Me)3), 31.0 (s, C(Me)3).
[(C^Npz^N)Au(1,3,7,9-tetramethylxanthin-8-ylidene)]BF4 (3). A
mixture of 1 (50 mg, 0.087 mmol), 1,3,7,9-tetramethylxanthinium
tetraﬂuoroborate (26 mg, 0.087 mmol), and KOtBu (12 mg, 0.104
mmol) was stirred in distilled toluene (7 mL) at 80 °C overnight,
leading to the formation of an orange precipitate. After the solution
was cooled to room temperature, the solvent was evaporated, and the
orange solid was dissolved in dichloromethane. The orange solution
was ﬁltered through Celite and concentrated under reduced pressure.
Upon addition of diethyl ether, a yellow precipitate formed and was
collected, washed with water (3 × 3 mL), and dried to aﬀord the pure
product as a yellow powder (46 mg, 0.055 mmol, 67% yield). Anal.
Calcd for C33H38N6O2AuBF6 (834.3): C, 47.50; H, 4.59; N, 10.07.
Found: C, 47.41; H, 4.50; N, 10.26. 1H NMR (CD2Cl2, 300.13 MHz):
δ 8.94 (s, 2H, H2), 7.74 (d, 3JH−H = 8.2 Hz, 2H, H
5), 7.43 (dd, 3JH−H =
8.4 Hz, 4JH−H = 2.0 Hz, 2H, H
6), 7.20 (d, 4JH−H = 2.0 Hz, 2H, H
8),
4.29 (s, 3H, N−Me18), 4.18 (s, 3H, N−Me11), 3.93 (s, 3H, N−Me13),
3.45 (s, 3H, N−Me15), 1.18 (s, 18H, tBu). 13C{1H} NMR (CD2Cl2,
75.48 MHz): δ 165.3 (s, C9), 159.1 (s, C10), 158.5 (s, C3/4), 157.3 (s,
C3/4), 154.0 (s, C16), 151.0 (s, C14), 144.6 (s, C7), 141.7 (s, C17), 139.8
(s, C2), 134.0 (s, C8), 127.3 (s, C5), 125.9 (s, C6), 111.1 (s, C12), 40.2
(s, N−Me18), 38.7 (s, N−Me11), 35.7 (s, C(Me)3), 32.5 (s, N−Me13),
31.0 (s, C(Me)3), 29.03 (s, N−Me15).
(C^Npz^N)Au(6-thioguanine) (4). A mixture of 1 (50 mg, 0.087
mmol), K2CO3 (24 mg, 0.146 mmol), and 6-thioguanine (15 mg,
0.087 mmol) was stirred in a 1/1 acetone/MeOH mixture (10 mL) at
room temperature for 3 h. The solution was evaporated to dryness,
and the obtained orange solid was dissolved in the minimum amount
of MeOH and diluted with DCM to a ﬁnal volume of 20 mL. The
solution was ﬁltered over Celite and concentrated under vacuum. After
addition of diethyl ether, an orange precipitate was obtained and
ﬁltered, washed with water (2 × 3 mL), and dried to aﬀord the
product with three waters of hydration as an orange powder (58 mg,
89% yield). Anal. Calcd for C29H30N7AuS·3H2O (759.7): C, 45.85; H,
4.78; N, 12.91. Found: C, 46.22; H, 4.32; N, 12.15. 1H NMR (DMSO-
d6, 300.13 MHz): δ 9.24 (s, 2H, H
2), 8.32 (s, 1H, H10), 7.88 (d, 3JH−H
= 8.2 Hz, 2H, H5), 7.57 (d, 4JH−H = 1.9 Hz, 2H, H
8), 7.32 (s, 1H, NH),
7.23 (dd, 3JH−H = 8.2 Hz,
4JH−H = 1.9 Hz, 2H, H
6), 5.11 (broad s, 2H,
NH2), 1.11 (s, 18H,
tBu). 13C{1H} NMR (DMSO-d6, 75.48 MHz):
170.2 (s, C9), 156.7 (s, C3/4), 155.6 (s, C3/4), 154.5 (s, C7), 144.4 (s,
C10), 139.3 (s, C2), 131.1 (s, C8), 125.9 (s, C5), 123.4 (s, C6), 79.2 (s,
C10), 35.0 (s, C(CH3)3), 30.8 (s, CH3).
X-ray Crystallography. A summary of the crystallographic
information is collected in Table S1. Crystals of 2·toluene were
mounted on a MiTeGen MicroMesh and ﬁxed in a cold nitrogen
stream. Diﬀraction intensities were recorded at 140 K on a Rigaku HG
Saturn724+ (2 × 2 bin mode) equipped with Mo Kα radiation. Data
collection, reﬁnement, and reduction were performed using the
CrystalClear-SM Expert 3.1 b27 software, and the absorption
correction was done at this stage.63 Both structures were solved
using SHELXT and reﬁned by full-matrix least-squares methods on F2
with SHELXL.64 Non-hydrogen atoms were reﬁned with anisotropic
thermal parameters. Hydrogen atoms were included at idealized
positions. No missed symmetry was reported by PLATON.65
Computer programs used in this analysis were run through
WinGX.66 Scattering factors for neutral atoms were taken from the
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literature.67 In the structure of 2·toluene, the PF6
− anion showed
statistic disorder that could not be modeled. For this reason, these
atoms were restrained with eﬀective standard deviation s so that their
Uij components approximate isotropic behavior. However, two large
peaks of residual electron density close to the phosphorus atom with
no chemical meaning were observed. This caused three A-alerts in the
check-cif for this complex. CCDC 1521266 (2) contains the
supplementary crystallographic data for this paper. These data can
be obtained free of charge from The Cambridge Crystallographic Data
Centre via www.ccdc.cam.ac.uk/data_request/cif.
Biological Testing. Antiproliferation Assay. Human HL60 and
A549 cancer cell lines (from ECACC) were cultured in RPMI 1640
medium with 10% fetal calf serum, 2 mM L-glutamine, 100 units/mL
penicillin, and 100 μg/mL streptomycin (Invitrogen). Cells were
maintained in a humidiﬁed atmosphere at 37 °C and 5% CO2. The
human MCF-7 cancer cell line (from ECACC) and the human fetal
ﬁbroblast (MRC-5) cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium with 10% fetal calf serum, 2 mM L-glutamine, 100 units/mL
penicillin, and 100 μg/mL streptomycin (Invitrogen). Cells were
maintained in a humidiﬁed atmosphere at 37 °C with 5% CO2.
Inhibition of cancer cell proliferation was measured by the 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium (MTS) assay using the CellTiter 96 Aqueous One
Solution Cell Proliferation Assay (Promega) and following the
manufacturer’s instructions. Brieﬂy, cells (3 × 104/100 μL for HL60,
8 × 103/100 μL for both A549 and MCF-7, and 2 × 103/100 μL for
MRC-5) were seeded in 96-well plates and left untreated or treated
with 1 μL of DMSO (vehicle control) or 1 μL of complex diluted in
DMSO at diﬀerent concentrations in triplicate for 72 h at 37 °C with
5% CO2. Following this, the MTS assay reagent was added for 4 h, and
the absorbance measured at 490 nm using a Polarstar Optima
microplate reader (BMG Labtech). IC50 values were calculated using
GraphPad Prism version 5.0 software.
Uptake Study. A549 and MCF-7 cells were grown in 75 cm2 ﬂasks
up to 70% of conﬂuence in 10 mL of culture medium. Compounds 1−
3 were added to the ﬂasks (100 μL of 1 mM solution in DMSO) and
incubated for 6 h at 37 °C with 5% CO2. As negative controls, cells
were incubated with DMSO alone under the same conditions. After
removal of the medium and washing of the cells with phosphate-
buﬀered saline (PBS) (pH 7.4), the cells were detached using a trypsin
solution. After quenching of trypsin with fresh medium, centrifugation,
and removal of the supernatant, the cell pellet was resuspended in 1
mL of PBS (pH 7.4) and split into two 500 μL aliquots for metal and
protein quantiﬁcation. The number of cells (expressed in millions of
cells) in each sample was determined by measuring the protein
content of the treated sample using a BCA assay (ThermoFischer
Scientiﬁc) corrected by the amount of protein/106 cells, which was
determined for each cell type by measuring the protein content of an
untreated sample and dividing by the corresponding number of cells
measured with a hematocytometer following a reported procedure.68
Microwave digestion was used to solvate the samples to liquid form.
Nitric acid and hydrogen peroxide were used in a Milestone Ethos 1
microwave system using an SK-10 10-place carousel. The digest was
ramped to 200 °C in 15 min and held at 200 °C for 15 min. The
sample was weighed into a microwave vessel before digestion and
decanted and rinsed into a preweighed PFA bottle after digestion. ICP-
MS samples were spiked with rhodium internal standard and run on a
Thermo X series 1 ICP mass spectrometer. Isotopes selected were
63Cu, 65Cu, 107Ag, 109Ag, and 197Au. Certiﬁed standards and an
independent reference were used for accuracy. Acid blanks were run
through the system and subtracted from sample measurements before
corrections for dilution.
FRET Assay. The initial FRET melting screen was performed using a




TTA-GGG-TTA-GGG-TTA-GGG]-TAMRA-3′), and DSFRET (5′-
FAM-d[TAT-AGC-TAT-A-HEG(18)-TAT-AGC-TAT-A]-TAMRA-
3′). The labeled oligonucleotides (the donor ﬂuorophore, FAM, was 6-
carboxyﬂuorescein; the acceptor ﬂuorophore, TAMRA, was 6-
carboxytetramethylrhodamine) were prepared as a 220 nM solution
in 10 mM sodium cacodylate buﬀer at the indicated pH with 100 mM
sodium chloride and then thermally annealed. Strip tubes (QIAgen)
were prepared by aliquoting 18 μL of the annealed DNA followed by 2
μL of the compound solutions. Control samples for each run were
prepared with the same quantity of DMSO with the DNA in buﬀer.
Fluorescence melting curves were determined in a QIAgen Rotor-
Gene Q-series PCR machine using a total reaction volume of 20 μL.
Measurements were made with excitation at 470 nm and detection at
510 nm. Final analysis of the data was carried out using QIAgen Rotor-
Gene Q-series software and Origin or Excel.
Fluorescence Polarization Assay. The ﬂuorescence polarization
assay was carried out on a BMG Labtech CLARIOstar microplate
reader with a ﬂuorescence polarization optic measuring at 490/520
nm. Black, ﬂat-bottom, untreated polystyrene Corning 96-well black
plates were used, and all of the reagents used in the assay were
biological grade and purchased from Sigma-Aldrich, Novabiochem, or
Thermo Fisher Scientiﬁc. All of the solutions were made using Milli-Q
water. Samples and the positive control (wild-type p53, 4 mM) were
dissolved in DMSO. Each well was prepared with 90 μL of a working
solution of HDM2 (11.11 nM) and ﬂuorescently tagged high-aﬃnity
peptide (FAM-LTFEHYWAQLTS-CONH2, 11.11 nM) in PBS with
0.05% Tween-20 at pH 7.4. For the assay, 10 μL of either sample or
positive or negative control was added to each well to obtain a ﬁnal
volume of 100 μL and 10 nM concentration of protein and tagged
peptide. For screening purposes, the samples were tested in duplicate
at a concentration of 100 μM. Compounds that showed inhibition
were tested for IC50 using seven diﬀerent concentrations in triplicate.
The experiment was repeated to conﬁrm the result. Each plate
contained a positive control (wild-type p53, ﬁnal concentration 400
μM) and a negative control (DMSO), both in triplicate. Before the
plate was read, it was shaken manually to provide appropriate mixing
and incubated at room temperature for 30 min, and the absence of
bubbles was veriﬁed. Total ﬂuorescence was also recorded to identify
potential interference due to intrinsic ﬂuorescence or quenching from
the samples. Data analysis was performed with GraphPad Prism and
Microsoft Excel. IC50 results were analyzed using nonlinear regression
for the logarithm of the inhibitor versus response with variable slope.
NMR Spectroscopy. The NMR spectra were recorded at 25 °C in
25 mM PBS (pH 7.4), 1% DMSO-d6 with D2O as the solvent on an
ultra-compact 800 MHz Bruker Avance III NMR spectrometer
equipped with an inverse triple resonance (H/C/N) z-gradient
probe head. For sample preparation, ligand 2 was lyophilized twice
with 99% D2O and once ﬁnal in 99.99% D2O from Sigma-Aldrich.
Final concentrations were 13.5 μM MDM2 and 500 μM 2. Chemical
shift assignments for 2 were obtained at 800 MHz by means of COSY,
TOCSY, NOESY (800 ms), and HSQC 2D NMR experiments. STD
NMR experiments were carried out using a pseudo-2D pulse sequence
including spoil pulses to destroy residual magnetization during the
relaxation delay (two trim pulses of 2.5 and 5 ms followed by a 3 ms
gradient pulse on the Z axis). For selective saturation of MDM2,
cascades of 49 ms Gaussian-shaped pulses were used with a 1 ms delay
between successive pulses. Total saturation times for STD measure-
ments were 4 s (for binding detection) and 0.5 s (for binding epitope
determination) on experiments consisting of 1024 scans. The short
saturation time for the determination of the binding epitope avoids the
introduction of artifacts due to diﬀerent relaxation properties of
protons of 2. Selective saturation of the protein was achieved by
setting the on-resonance frequency at 0 ppm in order to produce
saturation of the aliphatic side chains of the protein. The irradiation
frequency was shifted to 40 ppm for the reference (of f-resonance)
spectrum. The absence of direct irradiation of ligand 1H signals was
veriﬁed by blank STD NMR experiments (without protein). The
binding epitope was determined by assigning 100% relative value to
the most intense proton and normalizing the values of the remaining
ligand protons against it.
Docking Calculations. Compound 2 was minimized using density
functional theory with the B3LYP hybrid functional and the 6-311+
+G** basis set. For gold atoms, the LANL2DZ basis set and an
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eﬀective core potential (ECP) to treat the core electrons were used.
Frequency calculations were performed to ensure that a stationary
point was reached. Single-point calculations and population analysis
were also performed using the TPSS functional69 in combination with
Grimme’s D3 dispersion correction using Becke−Johnson damping.70
The def2-TZVPP basis set was used.71 All of the calculations were
performed using Gaussian 09. Charge ﬁtting was performed using the
RESP ﬁtting method provided by antechamber72 with populations
obtained from both functionals described above. The gold atom, which
is not supported by the Autodock programs, was swapped with a
dummy atom (C), and the ligand was then prepared for docking using
AutoDockTools4.73 MDM2 (PDB entry 1T4E) was prepared with
UCSF Chimera74 for protonation and subsequent relaxation of the
hydrogens. A ﬁnal step of preparation with AutoDockTools473 was
necessary to convert the ﬁle to pdbqt format and introduce ﬂexibility
to the residues in the binding pocket: Gln 72, Met 62, Phe 55, Val 93,
Ile 61, Ser 17, and Leu 54. Docking was performed with AutoDock
4.2.374 using a genetic algorithm (20 runs, medium evaluation), and
the results were compared with NMR data to identify the binding pose
(see NMR Spectroscopy). Replacing the gold atom with a dummy
carbon atom is a simpliﬁcation chosen after evaluation of the
experimental results and with a speciﬁc aim. First, compound 2 is
unlikely to interact with sulfur centers, as highlighted in Reaction of 2
with Glutathione, thus excluding a main interaction characteristic of
some gold complexes. Second, from ﬂuorescence polarization assays
we identiﬁed displacement of the ﬂuorescent probe from MDM2,
which directed us to investigate the classic binding pocket of the
protein. The pocket is rich in hydrophobic residues, and interactions
with hydrophobic groups are a dominant motif in MDM2 binding,
similarly to the natural substrate. The charge of the gold atom was
determined at a quantum-mechanical level and assigned to the dummy
atom, thus covering electrostatic contributions. Gold is fairly shielded
by the methyl groups of the benzimidazole ligand and their
orientation, thus minimizing the opportunity for direct contact. The
method chosen allowed simple generation of a number of varied
conformations and orientations of compound 2 in the binding pocket.
Importantly, all of the generated poses were evaluated against NMR
results independently by their docking scores, and the choice of the
binding pose was based exclusively on experimental data, substantially
nullifying the estimation factor related to the replacement of the gold
atom with a dummy atom.
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